Olaparib: Myelodysplastic syndrome/acute myeloid leukaemia.

A Phase III study was conducted on 357 patients between January 2019 and June 2020, and it reported a case of a woman with BRCA-mutated advanced ovarian cancer who developed myelodysplastic syndrome/acute myeloid leukemia while being treated with olaparib. The woman had been receiving platinum-based chemotherapy and had recently started olaparib treatment. The case was reported in France, but no further details about the patient's age, treatment duration, or outcome were provided. [Extracted from the article]